A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation

A systematic review and meta-analysis of cohort studies on the potential association between NAFLD/MAFLD and risk of incident atrial fibrillation

Background and objectiveThe association between atrial fibrillation (AF) and non-alcoholic fatty liver disease (NAFLD) or metabolic-associated fatty liver disease (MAFLD) has been explored in recent cohort studies, however, the results have been controversial and inconclusive. This meta-analysis aim...

Full description

Bibliographic Details
Main Authors:	Ben‐Gang Zhou, Sheng-Yong Ju, Yu-Zhou Mei, Xin Jiang, Meng Wang, Ai-Jing Zheng, Yan-Bing Ding
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Endocrinology
Subjects:	metabolic dysfunction-associated fatty liver disease atrial fibrillation systematic review meta-analysis cohort studies non-alcoholic fatty liver disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1160532/full

Similar Items

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

A comparison of NAFLD and MAFLD diagnostic criteria in contemporary urban healthy adults in China: a cross-sectional study
by: Qiling Liu, et al.
Published: (2022-11-01)

Non-alcoholic Fatty Liver Disease and the Risk of Incident Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study
by: JungMin Choi, et al.
Published: (2022-03-01)

Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD
by: Jin Imai, et al.
Published: (2024-06-01)

The Transition of Cardiovascular Disease Risks from NAFLD to MAFLD
by: Zifeng Yang, et al.
Published: (2023-05-01)

Pediatric vs. adult NAFLD to MAFLD transition: a welcome but tangled path
by: Angelo Colucci, et al.
Published: (2021-08-01)

Comparison of MAFLD and NAFLD Characteristics in Children
by: Yunfei Xing, et al.
Published: (2023-03-01)

COVID-19 and MAFLD/NAFLD: An updated review
by: Ali Nowroozi, et al.
Published: (2023-03-01)

Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
by: Zhe Wang, et al.
Published: (2022-10-01)

Relations of Liver Fat With Prevalent and Incident Atrial Fibrillation in the Framingham Heart Study
by: Michelle T. Long, et al.
Published: (2017-05-01)

Identification of key genes increasing susceptibility to atrial fibrillation in nonalcoholic fatty liver disease and the potential mechanisms: mitochondrial dysfunction and systemic inflammation
by: Baiyin Zhong, et al.
Published: (2024-03-01)

Editorial: The NAFLD-MAFLD conundrum
by: Andrea Dalbeni, et al.
Published: (2023-09-01)

Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis
by: Limin Cao, et al.
Published: (2024-03-01)

Effect of obesity and obesity trajectories on the risk of cardiovascular diseases in adult male with incident NAFLD in Northern China
by: HU Shi-qi, LAN Yan-qi, WU Shou-ling, WANG Xiao-mo, CHEN Shuo-hua, WANG Guo-dong, WANG Li
Published: (2022-05-01)

Correlation between the triglyceride-glucose index and the onset of atrial fibrillation in patients with non-alcoholic fatty liver disease
by: Yao Zhang, et al.
Published: (2023-05-01)

Circulating irisin levels in patients with MAFLD: an updated systematic review and meta-analysis
by: Chenglu Shen, et al.
Published: (2024-12-01)

Metabolic Dysfunction–Associated Fatty Liver Disease (MAFLD) and Thyroid Function in Childhood Obesity: A Vicious Circle?
by: Valeria Calcaterra, et al.
Published: (2024-02-01)

Association between the Triglyceride–Glucose Index and Non-Alcoholic Fatty Liver Disease in patients with Atrial Fibrillation
by: Xiaozhong Li, et al.
Published: (2023-09-01)

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
by: Hiroyuki Suzuki, et al.
Published: (2024-07-01)

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
by: Kamlesh K. Bhopale, et al.
Published: (2023-10-01)

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia
by: Shuhei Fukunaga, et al.
Published: (2024-10-01)

Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD – Reconciling the present with the pastKey points
by: Oyekoya T. Ayonrinde
Published: (2021-06-01)

Extracellular Vesicles in NAFLD/ALD: From Pathobiology to Therapy
by: Alejandra Hernández, et al.
Published: (2020-03-01)

Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies
by: Yi Zhang, et al.
Published: (2024-03-01)

Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Weiyi Qu, et al.
Published: (2021-10-01)

Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups
by: Eun Ju Cho, et al.
Published: (2024-09-01)

Synergistic effects of ursodeoxycholic acid, and quercetin on liver function and systemic inflammation in non-alcoholic fatty liver disease and atrial fibrillation patients
by: O.B. Teslenko, et al.
Published: (2024-06-01)

High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation
by: Raphaël Decoin, et al.
Published: (2022-08-01)

Nonalcoholic fatty liver disease as a predictor of atrial fibrillation: a systematic review and meta-analysis
by: Yaqiong Zhou, et al.
Published: (2017-09-01)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
by: Seogsong Jeong, et al.
Published: (2023-03-01)

The monocyte-to-high-density lipoprotein ratio is associated with the occurrence of atrial fibrillation among NAFLD patients: A propensity-matched analysis
by: Leigang Wang, et al.
Published: (2023-03-01)

Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis
by: Nan Yao, et al.
Published: (2022-06-01)

Non Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure
by: Alabagi Abdulla, et al.
Published: (2016-04-01)

The NAFLD–MAFLD debate through the lens of the Arab world
by: Mina Tharwat, et al.
Published: (2022-01-01)

Genetic implications in patients with NAFLD
by: Jakub Misiak, et al.
Published: (2024-01-01)

Effects of MAFLD defined by fatty liver index or ultrasonography on kidney function decline in the general population
by: Yu-Ji Lee, et al.
Published: (2024-09-01)

Association between serum cholinesterase and the prevalence of atrial fibrillation in Chinese hypertensive population: a cross-sectional study
by: Wenjing Xue, et al.
Published: (2023-11-01)

Comparison of the Diagnostic Performance of Steatosis Indices for Discrimination of CT-Diagnosed Metabolic Dysfunction-Associated Fatty Liver Disease
by: A. Lum Han, et al.
Published: (2022-07-01)

Too Much of a Good Thing? An Evolutionary Theory to Explain the Role of Ceramides in NAFLD
by: Annelise M. Poss, et al.
Published: (2020-07-01)

A Quantitative Systems Pharmacology Platform Reveals NAFLD Pathophysiological States and Targeting Strategies
by: Daniel E. Lefever, et al.
Published: (2022-06-01)